TG Therapeutics, Inc. (0VGI.L)
USD 31.97
(-5.69%)
USD 31.97
(-5.69%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 26.1 Million USD | 111.19% |
| 2022 | -187.62 Million USD | 45.06% |
| 2021 | -341.96 Million USD | -25.42% |
| 2020 | -272.67 Million USD | -62.93% |
| 2019 | -168.5 Million USD | 3.86% |
| 2018 | -173.39 Million USD | -46.84% |
| 2017 | -118.39 Million USD | -50.33% |
| 2016 | -78.9 Million USD | -27.42% |
| 2015 | -63.16 Million USD | -12.99% |
| 2014 | -55.71 Million USD | -227.9% |
| 2013 | -19.52 Million USD | 29.84% |
| 2012 | -24.94 Million USD | -2603.31% |
| 2011 | -881.97 Thousand USD | 83.6% |
| 2010 | 1.89 Million USD | -345.81% |
| 2009 | -1.73 Million USD | 72.51% |
| 2008 | -3.92 Million USD | 63.73% |
| 2007 | -11.98 Million USD | -21.7% |
| 2006 | -9.63 Million USD | 48.53% |
| 2005 | -19.08 Million USD | -217.28% |
| 2004 | -5.86 Million USD | -188.84% |
| 2003 | -2.1 Million USD | -40.64% |
| 2002 | -995.46 Thousand USD | 65.73% |
| 2001 | -3.04 Million USD | -1135.81% |
| 2000 | -3.08 Million USD | 86.39% |
| 1999 | -2.6 Million USD | -4.0% |
| 1998 | -3 Million USD | 53.7% |
| 1997 | -5.2 Million USD | -35.0% |
| 1996 | -3.7 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -9.18 Million USD | 27.78% |
| 2024 Q2 | 8.88 Million USD | 227.59% |
| 2024 Q3 | 15.1 Million USD | 42.45% |
| 2023 Q2 | -43.98 Million USD | -20.87% |
| 2023 Q4 | -12.39 Million USD | -110.8% |
| 2023 Q1 | -36.38 Million USD | 27.42% |
| 2023 FY | - USD | 111.19% |
| 2023 Q3 | 114.78 Million USD | 360.97% |
| 2022 Q3 | -34.04 Million USD | 9.21% |
| 2022 Q4 | -50.13 Million USD | -47.27% |
| 2022 Q2 | -37.49 Million USD | 43.38% |
| 2022 FY | - USD | 45.06% |
| 2022 Q1 | -66.22 Million USD | 28.22% |
| 2021 Q1 | -88.61 Million USD | -1.95% |
| 2021 FY | - USD | -25.42% |
| 2021 Q2 | -76.87 Million USD | 13.25% |
| 2021 Q3 | -84.59 Million USD | -10.05% |
| 2021 Q4 | -92.25 Million USD | -9.05% |
| 2020 Q4 | -86.92 Million USD | -1.6% |
| 2020 Q3 | -85.55 Million USD | -69.19% |
| 2020 Q1 | -49.83 Million USD | -32.28% |
| 2020 FY | - USD | -62.93% |
| 2020 Q2 | -50.56 Million USD | -1.47% |
| 2019 FY | - USD | 3.86% |
| 2019 Q4 | -37.67 Million USD | 37.62% |
| 2019 Q1 | -34.66 Million USD | 35.95% |
| 2019 Q2 | -35.11 Million USD | -1.29% |
| 2019 Q3 | -60.39 Million USD | -72.0% |
| 2018 Q3 | -34.3 Million USD | 22.64% |
| 2018 Q4 | -54.12 Million USD | -57.78% |
| 2018 FY | - USD | -46.84% |
| 2018 Q1 | -41.55 Million USD | -33.9% |
| 2018 Q2 | -44.34 Million USD | -6.71% |
| 2017 Q3 | -31.56 Million USD | -11.12% |
| 2017 FY | - USD | -50.33% |
| 2017 Q4 | -31.03 Million USD | 1.68% |
| 2017 Q1 | -27.66 Million USD | -15.14% |
| 2017 Q2 | -28.4 Million USD | -2.67% |
| 2016 FY | - USD | -27.42% |
| 2016 Q1 | -13.59 Million USD | 21.7% |
| 2016 Q2 | -15.66 Million USD | -15.16% |
| 2016 Q3 | -24.61 Million USD | -57.2% |
| 2016 Q4 | -24.02 Million USD | 2.4% |
| 2015 Q4 | -17.36 Million USD | -29.58% |
| 2015 Q1 | -14.34 Million USD | 22.74% |
| 2015 Q2 | -16.85 Million USD | -17.53% |
| 2015 Q3 | -13.4 Million USD | 20.46% |
| 2015 FY | - USD | -12.99% |
| 2014 Q4 | -18.56 Million USD | -7.81% |
| 2014 FY | - USD | -227.9% |
| 2014 Q3 | -17.21 Million USD | -46.5% |
| 2014 Q2 | -11.75 Million USD | -60.54% |
| 2014 Q1 | -7.32 Million USD | -178.82% |
| 2013 Q2 | -6.34 Million USD | -84.33% |
| 2013 Q1 | -3.44 Million USD | -87.22% |
| 2013 FY | - USD | 29.84% |
| 2013 Q4 | -2.62 Million USD | 39.16% |
| 2013 Q3 | -4.31 Million USD | 31.98% |
| 2012 Q3 | -2.94 Million USD | 5.13% |
| 2012 Q4 | -1.83 Million USD | 37.51% |
| 2012 FY | - USD | -2603.31% |
| 2012 Q1 | -17.59 Million USD | -474.3% |
| 2012 Q2 | -3.1 Million USD | 82.37% |
| 2011 Q2 | 1.9 Million USD | 136.34% |
| 2011 Q3 | -261.41 Thousand USD | -113.69% |
| 2011 FY | - USD | 83.6% |
| 2011 Q4 | -3.06 Million USD | -1071.7% |
| 2011 Q1 | -5.25 Million USD | -313.33% |
| 2010 Q1 | 413.61 Thousand USD | 194.24% |
| 2010 Q2 | -3.17 Million USD | -867.25% |
| 2010 Q3 | -1.34 Million USD | 57.6% |
| 2010 FY | - USD | -345.81% |
| 2010 Q4 | -1.27 Million USD | 5.54% |
| 2009 Q2 | -1.55 Million USD | -74.28% |
| 2009 Q3 | -552.18 Thousand USD | 64.59% |
| 2009 FY | - USD | 72.51% |
| 2009 Q4 | -438.91 Thousand USD | 20.51% |
| 2009 Q1 | -894.77 Thousand USD | -1723.88% |
| 2008 Q3 | -1.37 Million USD | 5.73% |
| 2008 Q4 | 55.1 Thousand USD | 104.0% |
| 2008 FY | - USD | 63.73% |
| 2008 Q1 | -1.6 Million USD | 15.94% |
| 2008 Q2 | -1.45 Million USD | 9.13% |
| 2007 Q1 | -2.57 Million USD | 18.49% |
| 2007 Q4 | -1.91 Million USD | 29.14% |
| 2007 Q3 | -2.69 Million USD | 45.08% |
| 2007 Q2 | -4.9 Million USD | -90.43% |
| 2007 FY | - USD | -21.7% |
| 2006 Q1 | -2.89 Million USD | 89.02% |
| 2006 Q2 | -2.34 Million USD | 19.21% |
| 2006 Q4 | -3.16 Million USD | -62.18% |
| 2006 Q3 | -1.95 Million USD | 16.75% |
| 2006 FY | - USD | 48.53% |
| 2005 Q4 | -26.4 Million USD | -1318.54% |
| 2005 Q2 | 10.4 Million USD | 828.65% |
| 2005 FY | - USD | -217.28% |
| 2005 Q1 | -1.42 Million USD | 18.45% |
| 2005 Q3 | -1.86 Million USD | -117.9% |
| 2004 Q3 | -2.2 Million USD | -115.4% |
| 2004 Q1 | -1.1 Million USD | 26.9% |
| 2004 Q4 | -1.75 Million USD | 20.56% |
| 2004 FY | - USD | -188.84% |
| 2004 Q2 | -1.02 Million USD | 7.86% |
| 2003 FY | - USD | -40.64% |
| 2003 Q1 | -380.2 Thousand USD | -7.4% |
| 2003 Q2 | -680.83 Thousand USD | -79.07% |
| 2003 Q3 | -1.98 Million USD | 169.38% |
| 2003 Q4 | -1.51 Million USD | -421.42% |
| 2002 Q1 | -618.38 Thousand USD | -272.91% |
| 2002 Q3 | -575.21 Thousand USD | -1401.3% |
| 2002 FY | - USD | 65.73% |
| 2002 Q4 | -354.01 Thousand USD | 38.45% |
| 2002 Q2 | -248.79 Thousand USD | 107.15% |
| 2001 Q4 | -546.98 Thousand USD | 151.58% |
| 2001 FY | - USD | -1135.81% |
| 2001 Q1 | -197.44 Thousand USD | -144.55% |
| 2001 Q2 | -1.45 Million USD | 61.35% |
| 2001 Q3 | -693.41 Thousand USD | 19.74% |
| 2000 Q3 | -944.65 Thousand USD | 70.14% |
| 2000 Q1 | -1.4 Million USD | -133.78% |
| 2000 FY | - USD | 86.39% |
| 2000 Q2 | -3.08 Million USD | -117.95% |
| 2000 Q4 | 2.34 Million USD | 649.86% |
| 1999 FY | - USD | -4.0% |
| 1999 Q4 | -600 Thousand USD | -20.0% |
| 1999 Q3 | -500 Thousand USD | 16.67% |
| 1999 Q2 | -699.99 Thousand USD | 40.0% |
| 1999 Q1 | -1 Million USD | -25.0% |
| 1998 FY | - USD | 53.7% |
| 1998 Q2 | 800 Thousand USD | 150.0% |
| 1998 Q3 | -1.3 Million USD | -285.71% |
| 1998 Q4 | -800 Thousand USD | 38.46% |
| 1998 Q1 | -1.4 Million USD | 17.65% |
| 1997 Q3 | -1.1 Million USD | 35.29% |
| 1997 Q4 | -1.6 Million USD | -54.55% |
| 1997 FY | - USD | -35.0% |
| 1997 Q1 | -800 Thousand USD | 33.33% |
| 1997 Q2 | -1.7 Million USD | -112.5% |
| 1996 Q3 | -1.2 Million USD | -100.0% |
| 1996 Q4 | -1.2 Million USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q1 | 100 Thousand USD | 0.0% |
| 1996 Q2 | -600 Thousand USD | -700.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 99.758% |
| Dynavax Technologies Corporation | 9.66 Million USD | -170.019% |
| Illumina, Inc. | -608 Million USD | 104.293% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 99.198% |
| Biogen Inc. | 2.37 Billion USD | 98.902% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 105.813% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 97.758% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 105.943% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 73.438% |
| Waters Corporation | 1.02 Billion USD | 97.447% |
| Perrigo Company plc | 646.2 Million USD | 95.961% |
| uniQure N.V. | -253.1 Million USD | 110.312% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 107.555% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 128.345% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 109.812% |
| bluebird bio, Inc. | -167.16 Million USD | 115.614% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 122.184% |
| Imunon, Inc. | -20.78 Million USD | 225.588% |
| Myriad Genetics, Inc. | -67.8 Million USD | 138.496% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 93.727% |
| Nektar Therapeutics | -243.1 Million USD | 110.736% |
| Editas Medicine, Inc. | -163.11 Million USD | 116.001% |
| Verastem, Inc. | -83.16 Million USD | 131.383% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 100.231% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 158.735% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 125.146% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 170.005% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 91.588% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 129.853% |
| Evolus, Inc. | -41.81 Million USD | 162.425% |
| Adicet Bio, Inc. | -136.53 Million USD | 119.116% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 129.664% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 99.439% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 117.387% |
| FibroGen, Inc. | -261.4 Million USD | 109.985% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 98.444% |
| OPKO Health, Inc. | -65.51 Million USD | 139.838% |
| Homology Medicines, Inc. | -47.75 Million USD | 154.653% |
| Geron Corporation | -174.78 Million USD | 114.933% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 111.441% |
| Exelixis, Inc. | 196.6 Million USD | 86.724% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 125.886% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 146.811% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 105.155% |
| Zoetis Inc. | 3.68 Billion USD | 99.292% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 111.6% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 151.61% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 99.433% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 172.335% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 111.347% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 75.906% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 94.225% |
| Blueprint Medicines Corporation | -474.61 Million USD | 105.499% |
| Insmed Incorporated | -654.73 Million USD | 103.986% |
| Incyte Corporation | 919.42 Million USD | 97.161% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 105.165% |